Maintenance therapy in ovarian cancer

Current Opinion in Oncology

Volumn 26, Issue 5, 2014, Pages 521-528

  Khalique, Saira ^a   Hook, Jane M ^b   Ledermann, Jonathan A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antiangiogenesis; maintenance therapy; ovarian cancer; poly ADP ribose polymerase inhibitors

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CEDIRANIB; CYTOTOXIC AGENT; FARLETUZUMAB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NINTEDANIB; NIRAPARIB; OLAPARIB; OREGOVOMAB; PACLITAXEL; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RUCAPARIB; SORAFENIB; TREBANANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VINATAFOLIDE;

BLEEDING; BRCA GENE; CANCER RECURRENCE; CANCER THERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENE; GENE MUTATION; HEADACHE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNE SYSTEM; LIVER DYSFUNCTION; MAINTENANCE CHEMOTHERAPY; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMBINATION REPAIR; REVIEW; TREATMENT OUTCOME; VOICE DISORDER; DISEASE FREE SURVIVAL; FEMALE; IMMUNOLOGY; OVARIAN NEOPLASMS;

ANGIOGENESIS INHIBITORS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS;

EID: 84906099838     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000110     Document Type: Review

References (50)

1. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2013 ; http: //seer. cancer.gov/csr/1975-2011/ [Accessed April 2014]
2. Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data. Lancet 2011; 377: 127-138
3. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinumbased treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27: 1419-1425
4. Mobus V, Wandt H, Frickhofen N, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: Intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007; 25: 4187-4193
5. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43
6. Katsumata N, Yasuda M, Isonishi S, et al. Long-Term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomized, controlled, open-label trial. Lancet Oncol 2013; 14: 1020-1026
7. Hoskins P, Vergote I, Cervantes A, et al. Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-Topotecan and carboplatin- paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 2010; 102: 1547-1556
8. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma.ANorth ThamesOvary Group Study. AnnOncol1997; 8: 327-333
9. Pasquier E, Carré M, Pourroy B, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004; 3: 1301-1310
10. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465
11. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinumpaclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 2009; 114: 195-198
12. Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2011; 122: 89-94
13. Mei L, Chen H, Wei DM, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev 2013; 6: CD007414
14. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebocontrolled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011; 29: 3798-3804
15. Horowitz N, Matulonis UA. New biologic agents for the treatment of gynecologic cancers. Hematol Oncol Clin North Am 2012; 26: 133-156
16. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045
17. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483
18. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496
19. Hall M, Gourley C, McNeish I, et al. Targeted antivascular therapies for ovarian cancer: Current evidence. Br J Cancer 2013; 108: 250-258
20. Monk BJ, Dalton H, Farley JH, et al. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol 2013; 86: 161-175
21. Oza A, Perren T, Swart A, et al. ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Amsterdam, The Netherlands: European Cancer Congress; 2013; abstr. 6. http: //eccamsterdam2013.ecco-org.eu/Scientific-Programme/ Abstract-search.aspx?abstractid8966
22. Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010; 119: 32-37
23. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27: 5601-5606
24. Du Bois A, Floquet A, Kim JW, et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international intergroup trial (AGO-OVAR16). J Clin Oncol 2013; 31 (Suppl): LBA5503
25. Herzog TJ, Scambia G, Kim BG, et al. A randomized phase II trial of maintenance therapy with sorafenib in front-line ovarian carcinoma. Gynecol Oncol 2013; 130: 25-30
26. du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: A randomized placebo controlled GCIG/ENGOT intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013; 23 (Suppl 11): 7
27. Ledermann J, Perren TJ, Raja F, et al. Randomized double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. Amsterdam, The Netherlands: European Cancer Conference; 2013; abstr. 10. http: //eccamsterdam2013.ecco-org.eu/Scientific- Programme/Abstract-search.aspx?abstractid8897
28. Raja FA, Griffin CL, Qian W, et al. Initial toxicity assessment of ICON6: A randomized trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer 2011; 105: 884-889
29. Monk BJ, Poveda A, Vergote I, et al. A phase 3, randomized, double-blind trial of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer: TRINOVA-1. Int J Gynecol Cancer 2013; 23 (Suppl 11): 49-50
30. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654-2663
31. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921
32. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 2010; 376: 245-251
33. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134
34. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615
35. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392
36. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). Lancet Oncol 2014; 15: 852-861
37. Vergote IB, Jimeno A, Joly F, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol 2014; 32: 320-326
38. Hall GD, Brown JM, Coleman RE, et al. Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomized phase III study. Br J Cancer 2004; 91: 621-626
39. Berek JS, Taylor PT, Gordon A, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004; 22: 3507-3516
40. Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009; 27: 418-425
41. Sabbatini P, Dupont J, Aghajanian C, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006; 12: 5503-5510
42. Sabbatini P, Harter P, Scambia G, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO: The MIMOSA study. J Clin Oncol 2013; 31: 1554-1561
43. McDermott D, Atkins M. PD-1 as a potential target in cancer therapy. Cancer Med 2013; 2: 662-673
44. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: Quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomized trial. Lancet Oncol 2013; 14: 236-243
45. Monk BJ, Huang HQ, Burger RA, et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 2013; 128: 573-578
46. Herzog TJ, Armstrong DK, Brady MF, et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol 2014; 132: 8-17
47. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642-1649
48. Berge EM, Doebele RC. Re-examination of maintenance therapy in nonsmall cell lung cancer with the advent of new anticancer agents. Drugs 2013; 73: 517-532
49. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer Inter-Group (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011; 21: 750-755
50. European Medicines Agency. Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man. 2013; http: //www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/ 01/WC500137126.pdf. [Accessed July 2014]